The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

<p>The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>

Saved in:

書目詳細資料
主要作者:	Seyed Reza Mousavi (13223324) (author)
其他作者:	Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
出版:	2025
主題:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
由: Anna Starshinova (22571846)
出版: (2025)

Supplementary Materials: Propagation of Beta bursts from the motor cortex to the motor units of multiple upper-limb muscles
由: Shlomi Haar (7537199)
出版: (2025)

Factors associated with EMG improvement after 6 months of follow-up of the uremic neuropathy in patients having a pathological first EMG.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Association between polyneuropathy presence and clinical/biological features during initial EMG in a 31-patient cohort.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Evolution of EMG parameters between first and second EMG among children having an End Stage Kidney Disease with an Uremic neuropathy (n = 24).
由: Arwa Yahyaoui (22683276)
出版: (2025)

Evolution of the pathological EMG in dialysis and no-dialysis group.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Comparison of electrophysiological abnormalities between pre-dialysis and dialysis Groups among children (n = 31) having an End Stage Kidney Disease.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Comparison between pre-dialysis and dialysis groups regarding clinical features and biological findings.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Comparison of Severity Grade and Normal EMG Between First and Second EMG Assessments in dialysis group at T2.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Participants’ follow-up between T1 and T2.
由: Arwa Yahyaoui (22683276)
出版: (2025)

Figure 6 – Source Data and MATLAB Code (dmPFC firing, neural selectivity, and LDA decoding)
由: Jinseon Yu (22598699)
出版: (2025)

Supplementary file 2_Navigating barriers and facilitators to lifestyle changes after bariatric surgery among Emirati adolescents: a qualitative study.pdf
由: Baraa A. Alries (22687031)
出版: (2025)

Supplementary file 1_Navigating barriers and facilitators to lifestyle changes after bariatric surgery among Emirati adolescents: a qualitative study.docx
由: Baraa A. Alries (22687031)
出版: (2025)

Figure 5 – Source Data (chemogenetic activation of TF synapses and behavioral rescue)
由: Jinseon Yu (22598699)
出版: (2025)

Table 1_Development and validation of a nomogram-based prediction model for hospital-acquired carbapenem-resistant Acinetobacter baumannii in critically ill patients: a multicenter retrospective cohort study.docx
由: Wenjing Jiang (7436471)
出版: (2025)

Table 2_Development and validation of a nomogram-based prediction model for hospital-acquired carbapenem-resistant Acinetobacter baumannii in critically ill patients: a multicenter retrospective cohort study.docx
由: Wenjing Jiang (7436471)
出版: (2025)

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Regio-Dependent Optoelectronic Properties of Oligomeric Peropyrenes
由: Haruki Sanematsu (21464607)
出版: (2025)

Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease
由: Mubeen Hussein Arawker (12965954)
出版: (2025)

Prevalence and detection rates of prespecified fetal anomalies <16 weeks gestational age according to first-trimester anatomy screening policy.
由: Jehan N. Karim (22683195)
出版: (2025)

Early detection of 14 fetal congenital anomalies based on the type of first-trimester anatomical screening policy.
由: Jehan N. Karim (22683195)
出版: (2025)

Response rates of trusts by regions as defined by Public Health England (PHE) at time of study.
由: Jehan N. Karim (22683195)
出版: (2025)

Survey of dysphagia protocol use (Carnaby et al., 2025)
由: Giselle D. Carnaby (22575401)
出版: (2025)

Comparison of hierarchical classifier performance among four machine learning models for the early-loss, intermediate-loss, and late/no-loss groups.
由: Raiki Yoshimura (22676573)
出版: (2025)

Comparison of multi-class classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
由: Raiki Yoshimura (22676573)
出版: (2025)

Comparison of binary classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
由: Raiki Yoshimura (22676573)
出版: (2025)

Comparison of performance of four machine learning models for long-term graft loss prediction.
由: Raiki Yoshimura (22676573)
出版: (2025)

Comparison of prediction performance with previously reported metrics.
由: Raiki Yoshimura (22676573)
出版: (2025)

Comparison of performance of four machine learning models for early graft loss prediction.
由: Raiki Yoshimura (22676573)
出版: (2025)

Predicting stratified groups in the validation cohort: (A) Workflows for the multi-class classification and hierarchical classification models are illustrated.
由: Raiki Yoshimura (22676573)
出版: (2025)

Stratification and characterization of groups showing different graft survival: (A) UMAP visualization of the stratified derivation cohort data based on the distance matrix from the RF clustering.
由: Raiki Yoshimura (22676573)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jtdmb5i622qh102sm60vsqk4c0